Aarti Drugs Limited Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2017
May 23, 2017 at 06:28 am EDT
Share
Aarti Drugs Limited reported audited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2017. For the quarter, on standalone basis, net sales/income from operations were INR 2,696.2 million compared with INR 2,969.5 million for the same period last year. Profit before exceptional and extraordinary items and tax was INR 290.6 million compared with INR 234.1 million for the same period last year. Profit before tax was INR 290.6 million compared with INR 234.1 million for the same period last year. Net profit for the period was INR 204.6 million or INR 8.57 basic and diluted per share as compared to INR 171.1 million or INR 7.07 basic and diluted per share for the same period last year.
For the year, on standalone basis, net sales/income from operations were INR 10,887.2 million compared with INR 10,707.3 million for the same period last year. Profit before exceptional and extraordinary items and tax was INR 1,065.4 million compared with INR 928.4 million for the same period last year. Profit before tax was INR 1,065.4 million compared with INR 928.4 million for the same period last year. Net profit for the period was INR 742.4 million or INR 30.78 basic and diluted per share as compared to INR 662.9 million or INR 27.37 basic and diluted per share for the same period last year.
For the quarter, on consolidated basis, net sales/income from operations were INR 2,989.0 million compared with INR 3,139.7 million for the same period last year. Profit before exceptional and extraordinary items and tax was INR 295.4 million compared with INR 248.9 million for the same period last year. Profit before tax was INR 295.4 million compared with INR 248.9 million for the same period last year. Net profit for the period was INR 207.3 million or INR 7.38 basic and diluted per share as compared to INR 185.9 million or INR 7.68 basic and diluted per share for the same period last year.
For the year, on consolidated basis, net sales/income from operations were INR 11,951.7 million compared with INR 11,348.8 million for the same period last year. Profit before exceptional and extraordinary items and tax was INR 1,147.7 million compared with INR 952.7 million for the same period last year. Profit before tax was INR 1,147.7 million compared with INR 952.7 million for the same period last year. Net profit for the period was INR 805.6 million or INR 33.40 basic and diluted per share as compared to INR 687.2 million or INR 28.38 basic and diluted per share for the same period last year.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
